Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | June 2009 |
| End Date: | June 2010 |
Phase 1 Study of MCP-3100 in Patients With Refractory or Relapsed Cancer
The purpose of this study is to see how safe the study drug is and to determine the best
dose to use in cancer patients in the future.
The study drug is designed to reduce the activity of a protein known as "heat shock protein
90", or "Hsp90". Hsp90 is found in every cell in the human body and normally helps those
cells (and the body) cope with stressful situations. In certain cancers, however, Hsp90
helps the cancer cells survive and grow. By reducing the activity of Hsp90, the study drug
may slow the growth, and reduce the survival, of those cancer cells.
This is a dose escalation study. As subjects participating in the study tolerate a specific
dose level, the new subjects entering will be given a higher dose of the study drug.
We found this trial at
3
sites
Fox Chase Cancer Center Fox Chase has earned the prestigious designation from the National Cancer...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials